Empresa PHAXIAM Therapeutics S.A. Euronext Paris
Acciones
PHXM
FR0011471135
Biotecnología e investigación médica
En tiempo real
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
2,93 EUR | -0,34 % | -0,17 % | -36,30 % |
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23/06/23 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23/06/23 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23/06/23 |
Cindy Fevre
CTO | Chief Tech/Sci/R&D Officer | - | 23/06/23 |
Céline Breda
CTO | Chief Tech/Sci/R&D Officer | 54 | 23/06/23 |
Karine Charton
PRN | Corporate Officer/Principal | - | 23/06/23 |
General Counsel | - | 23/06/23 | |
Human Resources Officer | - | 23/06/23 | |
Jérôme Bailly
PRN | Corporate Officer/Principal | 45 | 23/06/23 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Director/Board Member | 63 | 23/06/23 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23/06/23 |
Gil Beyen
BRD | Director/Board Member | 62 | 23/06/23 |
Martine George
BRD | Director/Board Member | 76 | 23/06/23 |
Director/Board Member | 66 | 23/06/23 | |
Didier Hoch
CHM | Chairman | 68 | 23/06/23 |
Leila Nicolas
BRD | Director/Board Member | - | 23/06/23 |
Robert Sebbag
BRD | Director/Board Member | 73 | 23/06/23 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 6 075 105 | 5 597 574 ( 92,14 %) | 250 ( 0,004115 %) | 92,14 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
250 | 0.00% | 805 $ |
Información de la empresa
Sector
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+2,49 % | 96,73 mil M | |
-0,47 % | 21,31 mil M | |
-16,61 % | 21,21 mil M | |
-5,01 % | 18,79 mil M | |
-42,14 % | 16,37 mil M | |
-27,40 % | 13,68 mil M | |
+1,44 % | 13,44 mil M | |
+21,29 % | 10,98 mil M | |
-21,79 % | 8560,73 M |
- Bolsa de valores
- Acciones
- Acción PHXM
- Acción PHXM
- Empresa PHAXIAM Therapeutics S.A.